Lakefront Biotherapeutics | GLPG - Interest Expense On Debt


Lakefront Biotherapeutics reported EUR1.72M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Incyte USD 569K 13K Mar/2026
Merck EUR 104M 17M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
UCB EUR 49M 29M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025